Hyperbaric oxygen therapy improves recovery at acute motor axonal neuropathy case

Acute motor axonal neuropathy (AMAN) is a rare immune-mediated disorder characterized by acute flaccid paralysis with elevated levels of GM1 antibodies. It is also known as a subtype of the Guillain-Barre syndrome (GBS) and develops since antigen s serve as antibodies in the spinal cord. We report a case diagnosed as AMAN with symptoms of ascending limb symmetrical weakness. A neurological examination revealed a flaccid paralysis with multiple cranial nerve palsies. Electromyography showed an axonal type of GBS. The patient refused bone marrow fluid aspiration. Intravenous immunoglobulin was administered at the high care unit. Unfortunately, despite the standard therapy, an optimal recovery was not obtained. Hyperbaric oxygen (HBO) therapy has been known to be common in illnesses and some clinical diseases. Although it has not been indicated for peripheral neuropathy, a remarkable recovery was soon visible in the HBO-treated AMAN case. The HBO mechanisms involved here are anti-inflammation and immunomodulation.

[1]  I. Sudiana,et al.  Protective Effect of Hyperbaric Oxygen Treatment on Axon Degeneration after Acute Motor Axonal Neuropathy , 2021, Autoimmune diseases.

[2]  I. Sudiana,et al.  Acute Motor Axonal Neuropathy Improvement 20 Days After Hyperbaric Oxygen Therapy , 2021, International medical case reports journal.

[3]  Tedy Juliandhy,et al.  Effects of Hyperbaric Oxygen on T helper 17/regulatory T Polarization in Antigen and Collagen-induced Arthritis: Hypoxia-inducible Factor-1α as a Target , 2020, Oman medical journal.

[4]  M. Tegenthoff,et al.  Neuroimaging markers of clinical progression in chronic inflammatory demyelinating polyradiculoneuropathy , 2019, Therapeutic advances in neurological disorders.

[5]  M. Salam,et al.  Prevalence and outcomes of Guillain-Barré syndrome among pediatrics in Saudi Arabia: a 10-year retrospective study , 2019, Neuropsychiatric disease and treatment.

[6]  R. Gold,et al.  Treatment of an acute motor and sensory axonal neuropathy with propionate in a 33-year-old male , 2018, Therapeutic advances in neurological disorders.

[7]  R. Comín,et al.  Experimental Guillain-Barre syndrome induced by immunization with gangliosides: Keyhole limpet hemocyanin is required for disease triggering. , 2017, Biochimica et biophysica acta. Molecular basis of disease.

[8]  N. Yuki,et al.  Polyclonal IgM and IgA block in vitro complement deposition mediated by anti-ganglioside antibodies in autoimmune neuropathies. , 2016, International immunopharmacology.

[9]  T. Jin,et al.  Circulating memory T follicular helper subsets, Tfh2 and Tfh17, participate in the pathogenesis of Guillain-Barré syndrome , 2016, Scientific Reports.

[10]  H. Tandel,et al.  GUILLAIN-BARRÉ SYNDROME (GBS): A REVIEW , 2016 .

[11]  Robert Estridge,et al.  Understanding Guillain-Barré syndrome , 2015, JAAPA : official journal of the American Academy of Physician Assistants.

[12]  Ji Zhang,et al.  A new animal model of spontaneous autoimmune peripheral polyneuropathy: implications for Guillain-Barré syndrome , 2014, Acta neuropathologica communications.

[13]  H. Endtz,et al.  Host Factors Determine Anti-GM1 Response Following Oral Challenge of Chickens with Guillain-Barré Syndrome Derived Campylobacter jejuni Strain GB11 , 2010, PloS one.

[14]  O. Reyes,et al.  Immunosuppressants: Neuroprotection and promoting neurological recovery following peripheral nerve and spinal cord lesions , 2005, Experimental Neurology.

[15]  S. Karamürsel,et al.  Effect of hyperbaric oxygen therapy on nerve regeneration in early diabetes , 2004, Microsurgery.

[16]  W. Brown,et al.  An acute axonal form of Guillain-Barré polyneuropathy. , 1986, Brain : a journal of neurology.